Loading
This European trial confirmed, independently of the American RTOG 9402 study, that PCV chemotherapy added to radiotherapy lengthens survival in anaplastic oligodendroglioma, with the largest benefit in tumours carrying the 1p/19q codeletion.
Phase 3 trial of 368 patients with anaplastic oligodendroglial tumours randomised to radiotherapy alone or radiotherapy followed by six cycles of PCV, reported at a median follow-up of 140 months.
Median overall survival was 42.3 months with PCV against 30.6 months without (hazard ratio 0.75); in the 80 patients with 1p/19q codeletion median survival was not reached with PCV against 112 months without (hazard ratio 0.56), and IDH mutation and MGMT methylation were also prognostic.
Together with RTOG 9402, this trial made radiotherapy followed by PCV the standard for 1p/19q-codeleted anaplastic oligodendroglioma; the CODEL trial is now comparing PCV with temozolomide.
Shares Procarbazine, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Vincristine.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Journal of Clinical Oncology.
Shares Procarbazine, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Vincristine.
Shares CODEL, EORTC 26951, Procarbazine, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Shares Vincristine, Journal of Clinical Oncology.
Shares Procarbazine, Vincristine, Journal of Clinical Oncology.
Shares Vincristine, Journal of Clinical Oncology.
Shares Procarbazine, Vincristine.